AmpTech, a technology incubator and commercialization center in Malvern, PA, is joining with BioStrategy Partners, Inc. (BioSP), a consortium of Pennsylvania academic centers and research institutions, to form an innovative network and functional ecosystem that offers research centers and institutions in Pennsylvania a unique program that will increase speed to market of technological devices.

The program uses a process designed to enhance early-stage intellectual property. The seven universities and research centers within BioStrategy Partners are Children’s Hospital of Philadelphia, Thomas Jefferson University/Jefferson Health, Penn State University, Temple University, Wistar Institute, and affiliate members University of the Sciences and the Lankenau Institute for Medical Research.

The partnership revolves around AmpTech’s 20,000 sq. ft building, which houses an infrastructure of scientific, engineering, and business capabilities with real-world expertise applied to this new germinator program. This program provides AmpTech with an exclusive option to develop new technologies that emerge from the partnership that will enable new company formation. It also allows AmpTech to deploy its team to engage industry adopters and potential investors early in the development of the selected cutting-edge intellectual property from these research centers. BioSP member institutions, whose collective research activity exceeded $1.6 billion in 2017, generate over 400 discoveries annually.

The AmpTech Germinator Program is modeled on two earlier BioSP germinator programs with leading global pharmaceutical companies. It has been tested and proven with several early stage projects in partnership with Temple University. “The addition of the AmpTech Germinator Program extends BioStrategy Partners’ efforts by advancing devices through an interconnected commercialization system of academic and industry partners,” says Stephen Nappi, president of BioSP. “Our two existing germinators at BioStrategy Partners have a history of working together to develop scalable discoveries in the pharmaceutical space, which will grow to include medical and other devices with the AmpTech partnership.” Nappi also is associate vice president, technology commercialization and business development at Temple University.

The AmpTech Germinator closes a critical gap in university and academic medical center research by taking an idea through the development stage and assessing both technical and market feasibility so that end users can identify it as a product of value early in the process. Its development and commercialization processes are simplified to ensure that quick actions are taken to bring the technology to a go/no-go decision.

“The AmpTech Germinator process has proven effective in connecting early-stage concepts to commercial adopters by aligning market feasibility and proof-of-concept prototyping within a limited budget and tight time constraints,” notes Roman Fedorovsky, president and CEO of AmpTech. “We’re excited to implement this process with BioStrategy Partners, which will further enhance medical device innovation around the Greater Philadelphia region.

According to Stephen Nappi, many institutions nationwide are seeking the same discovery, development, and commercial cohesion that the BioSP germinator programs have already achieved. By establishing new relationships such as this program with AmpTech, which moves the work of single institutions into a multi-institutional effort, BioSP is connecting a commercial system with a unique research and development system. These newly established relationships, which speak with one institutional voice instead of many, have been proven to reduce time and cost.

“Innovation is often very easy to talk about, but to progress an idea to a marketable product is a major challenge in the medical space,” says Michele Washko, program manager of BioSP. “BioStrategy Partners has introduced efficiencies that make it easier for all to reach this goal, and we look forward to working with AmpTech so that we may extend our work into the engineering space and bring new types of devices to market.”